Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 12/20 | 0.47 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.43 |
| ▸ | ITGAV | P06756 | 1/20 | 0.43 |
| ▸ | TLR2 | O60603 | 1/20 | 0.41 |
| ▸ | TGM2 | P21980 | 1/20 | 0.41 |
| ▸ | NPY1R | P25929 | 2/20 | 0.41 |
| ▸ | ALB | P02768 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19351729 | 0.99 | FOLH1 (0.48) | FOLH1ITGB3ITGAVTGM2NPY1R | |
| SCHEMBL23424692 | 0.89 | FOLH1 (0.56) | FOLH1ITGB3ITGAVTLR2 | |
| SCHEMBL24491163 | 0.86 | FOLH1 (0.64) | FOLH1 | |
| SCHEMBL24491164 | 0.86 | FOLH1 (0.64) | FOLH1 | |
| SCHEMBL17190068 | 0.85 | FOLH1 (0.58) | FOLH1ITGB3ITGAVTLR2NPY1R | |
| SCHEMBL23974147 | 0.85 | FOLH1 (0.57) | FOLH1 | |
| SCHEMBL22958139 | 0.84 | FOLH1 (0.48) | FOLH1ITGB3ITGAV | |
| SCHEMBL19442790 | 0.84 | FOLH1 (0.51) | FOLH1ITGB3ITGAVALB | |
| SCHEMBL15739345 | 0.83 | FOLH1 (0.49) | FOLH1ITGB3ITGAV | |
| SCHEMBL17190070 | 0.81 | FOLH1 (0.48) | FOLH1ITGB3ITGAVTGM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10912840-B2 | Conjugates for treating diseases caused by PSMA expressing cells | ENDOCYTE, INC. (US) | 2021-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10912840-B2 | Conjugates for treating diseases caused by PSMA expressing cells | FOLH1, KLK3, CD47 | FOLH1 1/4885ITGB3 271/4885ITGAV 473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.